Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. It is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.
企業コードANIK
会社名Anika Therapeutics Inc
上場日May 16, 1985
最高経営責任者「CEO」Dr. Cheryl Renee Blanchard, Ph.D.
従業員数288
証券種類Ordinary Share
決算期末May 16
本社所在地32 Wiggins Ave
都市BEDFORD
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号01730-2315
電話番号17814579000
ウェブサイトhttps://anika.com/
企業コードANIK
上場日May 16, 1985
最高経営責任者「CEO」Dr. Cheryl Renee Blanchard, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし